As the demand for innovative oncology treatments continues to grow worldwide, Tucatinib 150mg Tablets have become a crucial therapy for patients diagnosed with HER2-positive metastatic breast cancer. India has emerged as a leading source of high-quality oncology medicines, and Cordium Pharmaceuticals Pvt Ltd is recognized as a trusted exporter and global supplier of Tucatinib tablets, ensuring reliable access to healthcare providers, hospitals, distributors, and pharmaceutical importers across multiple international markets.
With a strong commitment to quality, compliance, and patient care, Cordium Pharmaceuticals offers fast, secure, and dependable delivery to major markets including the United States, Germany, United Kingdom, Netherlands, South Africa, United Arab Emirates, Brazil, Singapore, Australia, and Canada.
What is Tucatinib 150mg?
Tucatinib 150mg is an oral tyrosine kinase inhibitor (TKI) specifically designed to target the HER2 receptor. It is commonly prescribed in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, including cases where cancer has spread to the brain.
Unlike broader HER2 inhibitors, Tucatinib selectively inhibits HER2 signaling pathways, helping to slow tumor progression while minimizing effects on healthy cells.
Key Product Information
Product Name Tucatinib Tablets
Strength 150mg
Dosage Form Oral Tablets
Therapeutic Category Oncology / Anti-Cancer
Drug Class HER2 Tyrosine Kinase Inhibitor
Route of Administration Oral
Packaging Export-Grade Secure Packaging
Storage Store below 25°C in a dry place
Manufacturer/Supplier Cordium Pharmaceuticals Pvt Ltd
Benefits of Tucatinib 150mg Tablets
Targeted HER2 Inhibition
Tucatinib specifically targets HER2-positive cancer cells, reducing disease progression while preserving healthy tissue.
Effective in Brain Metastases
Clinical studies have shown significant benefits in patients with HER2-positive breast cancer that has spread to the brain.
Improved Progression-Free Survival
The therapy helps delay cancer progression and supports better long-term disease management.
Oral Administration
Convenient tablet form enables easier treatment adherence compared to some injectable therapies.
Combination Therapy Advantage
Often prescribed alongside trastuzumab and capecitabine to enhance treatment effectiveness.
Therapeutic Uses of Tucatinib
Tucatinib 150mg Tablets are indicated for:
HER2-positive metastatic breast cancer
Advanced HER2-positive breast cancer
Recurrent HER2-positive breast cancer
Breast cancer with brain metastases
Oncology treatment protocols involving HER2-targeted therapy
How Tucatinib Works
Cancer cells with HER2 overexpression grow rapidly due to abnormal signaling pathways. Tucatinib works by selectively blocking HER2 kinase activity, preventing cancer cell growth and multiplication.
This targeted mechanism helps:
Slow tumor growth
Reduce disease progression
Improve treatment outcomes
Support longer progression-free survival
Enhance overall disease control
Recommended Dosage
The dosage of Tucatinib should always be determined by a qualified oncologist based on:
Patient condition
Disease stage
Treatment response
Combination therapy requirements
Overall health profile
Patients should strictly follow medical advice and prescribed treatment schedules.
Possible Side Effects
Like all anti-cancer medications, Tucatinib may cause side effects.
Common side effects include:
Diarrhea
Nausea
Fatigue
Vomiting
Loss of appetite
Increased liver enzymes
Headache
Abdominal discomfort
Patients should immediately consult their healthcare provider if serious adverse reactions occur.
Global Demand for Tucatinib 150mg Tablets
The increasing prevalence of HER2-positive breast cancer has significantly increased global demand for Tucatinib.
Healthcare institutions and pharmaceutical importers from:
United States
Germany
United Kingdom
Netherlands
South Africa
United Arab Emirates
Brazil
Singapore
Australia
Canada
rely on trusted Indian exporters for uninterrupted access to oncology medicines.
Why Choose Cordium Pharmaceuticals Pvt Ltd?
Trusted Oncology Exporter from India
Cordium Pharmaceuticals has established itself as a reliable supplier of specialty oncology medicines for global markets.
International Quality Standards
Products are sourced and supplied following stringent pharmaceutical quality protocols.
Fast & Reliable Worldwide Delivery
Efficient logistics networks ensure timely shipments to hospitals, distributors, pharmacies, and healthcare institutions.
Secure Export Packaging
Products are packaged using export-grade standards to maintain integrity throughout transit.
Competitive Global Supply Solutions
Flexible procurement options support wholesalers, distributors, and institutional buyers.
Dedicated Customer Support
Professional assistance is available throughout the sourcing, documentation, and delivery process
With a strong commitment to quality, compliance, and patient care, Cordium Pharmaceuticals offers fast, secure, and dependable delivery to major markets including the United States, Germany, United Kingdom, Netherlands, South Africa, United Arab Emirates, Brazil, Singapore, Australia, and Canada.
What is Tucatinib 150mg?
Tucatinib 150mg is an oral tyrosine kinase inhibitor (TKI) specifically designed to target the HER2 receptor. It is commonly prescribed in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer, including cases where cancer has spread to the brain.
Unlike broader HER2 inhibitors, Tucatinib selectively inhibits HER2 signaling pathways, helping to slow tumor progression while minimizing effects on healthy cells.
Key Product Information
Product Name Tucatinib Tablets
Strength 150mg
Dosage Form Oral Tablets
Therapeutic Category Oncology / Anti-Cancer
Drug Class HER2 Tyrosine Kinase Inhibitor
Route of Administration Oral
Packaging Export-Grade Secure Packaging
Storage Store below 25°C in a dry place
Manufacturer/Supplier Cordium Pharmaceuticals Pvt Ltd
Benefits of Tucatinib 150mg Tablets
Targeted HER2 Inhibition
Tucatinib specifically targets HER2-positive cancer cells, reducing disease progression while preserving healthy tissue.
Effective in Brain Metastases
Clinical studies have shown significant benefits in patients with HER2-positive breast cancer that has spread to the brain.
Improved Progression-Free Survival
The therapy helps delay cancer progression and supports better long-term disease management.
Oral Administration
Convenient tablet form enables easier treatment adherence compared to some injectable therapies.
Combination Therapy Advantage
Often prescribed alongside trastuzumab and capecitabine to enhance treatment effectiveness.
Therapeutic Uses of Tucatinib
Tucatinib 150mg Tablets are indicated for:
HER2-positive metastatic breast cancer
Advanced HER2-positive breast cancer
Recurrent HER2-positive breast cancer
Breast cancer with brain metastases
Oncology treatment protocols involving HER2-targeted therapy
How Tucatinib Works
Cancer cells with HER2 overexpression grow rapidly due to abnormal signaling pathways. Tucatinib works by selectively blocking HER2 kinase activity, preventing cancer cell growth and multiplication.
This targeted mechanism helps:
Slow tumor growth
Reduce disease progression
Improve treatment outcomes
Support longer progression-free survival
Enhance overall disease control
Recommended Dosage
The dosage of Tucatinib should always be determined by a qualified oncologist based on:
Patient condition
Disease stage
Treatment response
Combination therapy requirements
Overall health profile
Patients should strictly follow medical advice and prescribed treatment schedules.
Possible Side Effects
Like all anti-cancer medications, Tucatinib may cause side effects.
Common side effects include:
Diarrhea
Nausea
Fatigue
Vomiting
Loss of appetite
Increased liver enzymes
Headache
Abdominal discomfort
Patients should immediately consult their healthcare provider if serious adverse reactions occur.
Global Demand for Tucatinib 150mg Tablets
The increasing prevalence of HER2-positive breast cancer has significantly increased global demand for Tucatinib.
Healthcare institutions and pharmaceutical importers from:
United States
Germany
United Kingdom
Netherlands
South Africa
United Arab Emirates
Brazil
Singapore
Australia
Canada
rely on trusted Indian exporters for uninterrupted access to oncology medicines.
Why Choose Cordium Pharmaceuticals Pvt Ltd?
Trusted Oncology Exporter from India
Cordium Pharmaceuticals has established itself as a reliable supplier of specialty oncology medicines for global markets.
International Quality Standards
Products are sourced and supplied following stringent pharmaceutical quality protocols.
Fast & Reliable Worldwide Delivery
Efficient logistics networks ensure timely shipments to hospitals, distributors, pharmacies, and healthcare institutions.
Secure Export Packaging
Products are packaged using export-grade standards to maintain integrity throughout transit.
Competitive Global Supply Solutions
Flexible procurement options support wholesalers, distributors, and institutional buyers.
Dedicated Customer Support
Professional assistance is available throughout the sourcing, documentation, and delivery process
Keywords
